Compare AVAH & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAH | OGN |
|---|---|---|
| Founded | 1984 | 1923 |
| Country | United States | United States |
| Employees | 35500 | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2021 | 2020 |
| Metric | AVAH | OGN |
|---|---|---|
| Price | $6.24 | $8.83 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | $9.88 | ★ $11.75 |
| AVG Volume (30 Days) | 1.1M | ★ 3.6M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.16% |
| EPS Growth | ★ 1850.00 | N/A |
| EPS | ★ 1.05 | 0.72 |
| Revenue | $2,433,199,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $7.31 | $0.42 |
| Revenue Next Year | $5.59 | $1.67 |
| P/E Ratio | ★ $6.30 | $9.60 |
| Revenue Growth | ★ 20.19 | N/A |
| 52 Week Low | $3.73 | $5.69 |
| 52 Week High | $10.32 | $13.25 |
| Indicator | AVAH | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.07 | 74.83 |
| Support Level | $6.02 | $8.32 |
| Resistance Level | $8.54 | $9.79 |
| Average True Range (ATR) | 0.27 | 0.42 |
| MACD | 0.03 | 0.26 |
| Stochastic Oscillator | 14.74 | 96.82 |
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.